PATRICIA Sampaio Fonseca Cincotto dos Santos Bueno

Dr. PATRICIA Sampaio Fonseca Cincotto dos Santos Bueno

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Sandra Maria BarbalhoSandra Maria Barbalho
Sandra Maria Barbalho
Rosa DireitoRosa Direito
Rosa Direito
LLLucas Fornari Laurindo
Lucas Fornari Laurindo
LMLedyane Taynara Marton
Ledyane Taynara Marton
Elen Landgraf GuiguerElen Landgraf Guiguer
Elen Landgraf Guiguer
Adriano Cressoni AraujoAdriano Cressoni Araujo
Adriano Cressoni Araujo
Neurodegenerative diseases, cardiovascular disease (CVD), hypertension, insulin resistance, cancer, and other degenerative processes commonly appear with aging. Ginkgo biloba (GB) is associated with several health benefits, including memory and cognitive improvement, in Alzheimer’s disease (AD), Parkinson’s disease (PD), and cancer. Its antiapoptotic, antioxidant, and anti-inflammatory actions have effects on cognition and other conditions associated with aging-related processes, such as insulin resistance, hypertension, and cardiovascular conditions. The aim of this study was to perform a narrative review of the effects of GB in some age-related conditions, such as neurodegenerative diseases, CVD, and cancer. PubMed, Cochrane, and Embase databases were searched, and the PRISMA guidelines were applied. Fourteen clinical trials were selected; the studies showed that GB can improve memory, cognition, memory scores, psychopathology, and the quality of life of patients. Moreover, it can improve cerebral blood flow supply, executive function, attention/concentration, non-verbal memory, and mood, and decrease stress, fasting serum glucose, glycated hemoglobin, insulin levels, body mass index, waist circumference, biomarkers of oxidative stress, the stability and progression of atherosclerotic plaques, and inflammation. Therefore, it is possible to conclude that the use of GB can provide benefits in the prevention and treatment of aging-related conditions.

Verified
Journal Article
Open access
PDF file
Lucas Fornari LaurindoLucas Fornari Laurindo
Lucas Fornari Laurindo
MMMariana Canevari de Maio
Mariana Canevari de Maio
Sandra Maria BarbalhoSandra Maria Barbalho
Sandra Maria Barbalho
Elen Landgraf GuiguerElen Landgraf Guiguer
Elen Landgraf Guiguer
Adriano Cressoni AraujoAdriano Cressoni Araujo
Adriano Cressoni Araujo
MBMarcelo Dib Bechara
Marcelo Dib Bechara
Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects the joints. Organokines can produce beneficial or harmful effects in this condition. Among RA patients, organokines have been associated with increased inflammation and cartilage degradation due to augmented cytokines and metalloproteinases production, respectively. This study aimed to perform a review to investigate the role of adipokines, osteokines, myokines, and hepatokines on RA progression. PubMed, Embase, Google Scholar, and Cochrane were searched, and 18 studies were selected, comprising more than 17,000 RA patients. Changes in the pattern of organokines secretion were identified, and these could directly or indirectly contribute to aggravating RA, promoting articular alterations, and predicting the disease activity. In addition, organokines have been implicated in higher radiographic damage, immune dysregulation, and angiogenesis. These can also act as RA potent regulators of cells proliferation, differentiation, and apoptosis, controlling osteoclasts, chondrocytes, and fibroblasts as well as immune cells chemotaxis to RA sites. Although much is already known, much more is still unknown, principally about the roles of organokines in the occurrence of RA extra-articular manifestations.

23 September 2023 in Diseases
Verified
Journal Article
Open access
PDF file
TMThais Menegucci
Thais Menegucci
ECEduardo Federighi Baisi Chagas
Eduardo Federighi Baisi Chagas
BZBarbara de Oliveira Zanuso
Barbara de Oliveira Zanuso
KBKarina Quesada Bechara
Karina Quesada Bechara
JHJesselina Francisco Dos Santos Haber
Jesselina Francisco Dos Santos Haber
Sandra Maria BarbalhoSandra Maria Barbalho
Sandra Maria Barbalho
Glycated hemoglobin (HbA1c) is used to assess glycemic control in Type 1 diabetes (DM1) patients. Apolipoproteins play an essential role in DM1 pathophysiology and may be associated with complications and HbA1c. This cross-sectional observational study of 81 children and adolescents of both sexes diagnosed with DM1 investigated the relationship between body fat distribution and lean mass with HbA1C and apolipoprotein values, analyzing biochemical and body composition measurements. A Shapiro–Wilk test with Lilliefors correction, a non-parametric Mann–Whitney test, and others were used with a significance level of 5%. The sample had a diagnosis time of 4.32 years and high blood glucose levels (mean 178.19 mg/dL) and HbA1c (mean 8.57%). Subjects also had a moderate level of adiposity, as indicated by arm and thigh fat areas. The study also found significant differences in the distribution of patients concerning levels of apolipoproteins A and B, with a smaller proportion of patients having undesirable levels. Finally, the study found a significant difference in the distribution of patients with estimated cardiovascular risk based on the ApoB/ApoA-I ratio. Conclusively, visceral fat in children and adolescents with DM1 may increase the risk of DM1 long-term complications owing to its association with elevated HbA1C and apolipoprotein values.

7 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Sandra Maria BarbalhoSandra Maria Barbalho
Sandra Maria Barbalho
KPKarina Torres Pomini
Karina Torres Pomini
ELEnzo Pereira de Lima
Enzo Pereira de Lima
JOJéssica da Silva Camarinha Oliveira
Jéssica da Silva Camarinha Oliveira
BBBeatriz Boaro
Beatriz Boaro
Lucas Fornari LaurindoLucas Fornari Laurindo
Lucas Fornari Laurindo
Cinobufagin (CB), a bufadienolide, has shown promising potential as an anticancer agent, particularly in combating lung cancer. This systematic review synthesizes preclinical evidence on CB’s effects against lung cancer, focusing on its mechanisms of action, efficacy, and potential clinical implications. We analyzed data from various preclinical studies involving both in vitro cell line models and in vivo animal models. The reviewed studies indicate that CB effectively reduces cell viability, induces apoptosis, and inhibits cell proliferation, migration, and invasion across multiple lung cancer cell lines and xenograft models. Specifically, CB was found to decrease cell viability and increase apoptosis in lung cancer cells by modulating key molecular pathways, including Bcl-2, Bax, cleaved caspases, caveolin-1, FLOT2, Akt, STAT3, and FOXO1. In vivo studies further demonstrated significant inhibition of tumor growth with minimal toxicity. However, limitations include reliance on in vitro models, which may not fully represent in vivo tumor dynamics, and a lack of long-term safety data. The studies also vary in their methodologies and cell line models, which may not accurately encompass all lung cancer subtypes or predict human responses. Despite these limitations, CB’s ability to target specific molecular pathways and its promising results in preclinical models suggest it could be a valuable addition to lung cancer treatment strategies. Our review suggests further clinical trials to validate its efficacy and safety in humans. Future research should explore combination therapies and optimize delivery methods to enhance clinical outcomes.

24 February 2024 in Diseases
Verified
Journal Article
Open access
PDF file
RMRafael Fagundes Melo
Rafael Fagundes Melo
Lucas Fornari LaurindoLucas Fornari Laurindo
Lucas Fornari Laurindo
KSKatia Sloan
Katia Sloan
LSLance A Sloan
Lance A Sloan
Adriano Cressoni AraujoAdriano Cressoni Araujo
Adriano Cressoni Araujo
ECEduardo Federighi Baisi Chagas
Eduardo Federighi Baisi Chagas
The treatment of Type 1 Diabetes Mellitus (T1DM) has always been a challenge for health professionals in relation to glycemic control. Increased body fat has been related to a worsening of the lipid profile and increased prevalence of dyslipidemia in this population, leading to negative repercussions on the control of cardiovascular risk. We aimed to investigate the distribution of lipid levels and the presence of dyslipidemia in children and adolescents with T1DM. A cross-sectional observational study was conducted with 81 individuals of both sexes (4–19 years) diagnosed with T1DM. Anthropometric and biochemical data were collected, in addition to data on physical activity level, sexual maturation stage, and insulin administration regimen. Lipid levels were categorized as normal, borderline, and elevated, and the presence of dyslipidemia was diagnosed by the presence of one or more altered lipid parameter. We noted a prevalence of dyslipidemia in 65.4% of the participants when considering borderline lipid values. Of those, 23.5% had one altered lipid level, and 42.0% had two or more. The main altered lipid levels were total cholesterol and triglycerides, followed by non-HDL-c. The main factor associated with the worsening of lipid levels was the increase in HbA1c. Sex had a significant effect on the levels of TC, HDL-c, and ApoA-I. The results of this study reinforce the need to monitor lipid profile in children and adolescents with T1DM, as well as the importance of early intervention in treating dyslipidemia, especially in patients with poor glycemic control.

1 February 2021 in Journal of Medical Primatology
Verified
Journal Article
Closed access
PDF file
RGRaul José Silva Girio
Raul José Silva Girio
TATatiana Morosini de Andrade‐Cruvinel
Tatiana Morosini de Andrade‐Cruvinel
SVSilvio Arruda Vasconcellos
Silvio Arruda Vasconcellos
CRCláudia Sampaio Fonseca Repetti
Cláudia Sampaio Fonseca Repetti
MFMilena Friolani
Milena Friolani
DTDaniel Teixeira
Daniel Teixeira